

IASLC



INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

IASLC 19th World Conference on Lung Cancer

September 23–26, 2018 Toronto, Canada
#WCLC2018

WWW.IASLC.ORG

Contacts:

Lisa Rivero

Vice President

lrivero@jpa.com | +1 617-657-1305

Becky Bunn, MSc

Public Relations Manager

Becky.Bunn@IASLC.org | +1 720-254-9509

Professor of Medicine, Hematology and Oncology; President of the American University of Beirut, to be Honored for Lifetime Scientific Achievement

The International Association for the Study of Lung Cancer to Present Joseph W. Cullen Prevention/Early Detection Award to Fadlo Khuri

DENVER – September 11 – Renowned oncologist, physician and professor, Fadlo R. Khuri, M.D., FACP, will be recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada. Dr. Khuri will accept the Joseph W. Cullen Prevention/Early Detection Award, honoring his lifetime scientific achievements in research on the prevention of thoracic malignancies.

Dr. Khuri is the current president of and a professor of medicine at the American University of Beirut in Lebanon, and also a professor on long term leave in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Khuri's research in the development of prognostic, molecular and therapeutic approaches for lung and thoracic cancers have led to advancements in prevention and early detection methods for patients suffering from these devastating diseases.

"Dr. Fadlo Khuri has for many years been a pioneer in pursuing the importance of early detection and particularly the treatment of premalignant conditions leading to lung cancer. He has also been a strong advocate for the concept of diagnosis of pre-malignancies and treatment approaches before the condition becomes an invasive cancer," said Fred R. Hirsch, M.D., Ph.D., CEO of the IASLC. "Dr. Khuri's groundbreaking studies and approaches are encouraging and inspiring in our fight to reduce lung cancer burden and mortality in the future through early intervention."

At Emory, he led the development of some of the most crucial cancer-related programs in Georgia and throughout the United States. An accomplished molecular oncologist, Dr. Khuri has directed pivotal research on oncolytic viral therapy, molecular-targeted therapeutic approaches and chemoprevention efforts for lung and head and neck cancers. His team has focused on the mechanisms of action of signal transduction inhibitors in lung and aerodigestive cancers. Dr. Khuri has published over 400 peer-reviewed articles in medical journals including *Nature Medicine*, *Journal of the National Cancer Institute*, *Cancer Research*, *Cancer*, and the *Journal of Clinical Oncology* and serves as editor-in-chief of the journal *Cancer*. As president of the American University of Beirut, he led the charge to make the campus completely tobacco free by August 31, 2018, receiving a Global Anti-Tobacco Leadership Recognition Award from the World Health Organization. Dr. Khuri was honored by the American Association for Cancer Research with its Richard and Hinda Rosenthal Award in 2013, is an elected Fellow of the American College of Physicians, the American Association for the Advancement of Science and is a Member of the Lebanese Academy of Sciences.

Dr. Khuri earned his bachelor's degree from Yale University and his medical degree from Columbia University, College of Physicians and Surgeons. He is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology.

Dr. Khuri will be honored on September 23, 2018 at the Opening Plenary Session at the IASLC 19th WCLC in Toronto, Canada. The IASLC WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The IASLC 19th WCLC will take place in Toronto on September 23-26, 2018. The Distinguished Awards are presented each year at the WCLC to the IASLC scientists who have demonstrated excellence in the field of lung cancer research and prevention.

About the WCLC:

The World Conference on Lung Cancer (WCLC) is the world's largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit www.iaslc.org. Follow the conference on social media with: **#WCLC2018**.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the *Journal of Thoracic Oncology*, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on [Twitter](#), [Facebook](#), [LinkedIn](#) and [Instagram](#).

###